載入中
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
前收盤價
US$165.69
+US$4.40 · +2.73%
盤中時間採用ET。市場資料可能有所延遲。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日內區間
目前US$165.69
52週區間
目前US$165.69
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
58
合理估值
情緒
60
多空交錯
風險
33
中等風險
動能
72
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
日內區間
目前US$165.69
52週區間
目前US$165.69
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.07億 USD | 3.83億 USD | 3.15億 USD | 2.83億 USD | 2.94億 USD |
| 銷貨成本 | 1.14億 USD | 9402.7萬 USD | 7557.5萬 USD | 6897.9萬 USD | 6662.7萬 USD |
| 毛利 | 3.93億 USD | 2.89億 USD | 2.39億 USD | 2.14億 USD | 2.27億 USD |
| 研究與開發 | 1.51億 USD | 1.36億 USD | 1.39億 USD | 1.23億 USD | 1.01億 USD |
| 銷售、一般及管理費用 | 3.29億 USD | 2.63億 USD | 2.24億 USD | 1.93億 USD | 1.79億 USD |
| 營業費用 | 4.8億 USD | 4.12億 USD | 3.68億 USD | 2.96億 USD | 2.6億 USD |
| 利息收入 | 1071.4萬 USD | 1110.5萬 USD | 916.4萬 USD | 237.5萬 USD | 128.8萬 USD |
| 利息支出 | 463.5萬 USD | 1004萬 USD | 1363.3萬 USD | 1372萬 USD | 1337.2萬 USD |
| 折舊和攤銷 | 4234.5萬 USD | 3992.2萬 USD | 3797.8萬 USD | 3594.6萬 USD | 3442.1萬 USD |
| 營業利益 | −8673.3萬 USD | −1.22億 USD | −1.29億 USD | −8231.3萬 USD | −3287.2萬 USD |
| 淨利 | −1.88億 USD | −1.46億 USD | −1.35億 USD | −9919.5萬 USD | −4959.3萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$192.89
上漲空間 16.42%報告持有此股票曝險的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR5.68億0.55%1031.91億 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI3.18億0.01%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2.45億0.31%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2.31億0.12%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32億0.29%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1.23億0.13%954億 USD0.05%US$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM8740.91萬0.55%158.4億 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO8592.11萬0.62%139.17億 USD0.24%US$356.78+0.94%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
